Potential Therapeutic Strategies for Targeting Y-Box-Binding Protein 1 in Cancers

Curr Cancer Drug Targets. 2021;21(11):897-906. doi: 10.2174/1568009621666210831125001.

Abstract

As one of the most conservative proteins in evolution, Y-box-binding protein 1 (YB-1) has long been considered as a potential cancer target. YB-1 is usually poorly expressed in normal cells and exerts cellular physiological functions such as DNA repair, pre-mRNA splicing and mRNA stabilizing. In cancer cells, the expression of YB-1 is up-regulated and undergoes nuclear translocation and contributes to tumorigenesis, angiogenesis, tumor proliferation, invasion, migration and chemotherapy drug resistance. During the past decades, a variety of pharmacological tools such as siRNA, shRNA, microRNA, circular RNA, lncRNA and various compounds have been developed to target YB-1 for cancer therapy. In this review, we describe the physiological characteristics of YB-1 in detail, highlight the role of YB-1 in tumors and summarize the current therapeutic methods for targeting YB-1 in cancer.

Keywords: Y-box-binding protein 1; cancer; circular RNA; lncRNA.; microRNA; nuclear translocation model; shRNA; siRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Line, Tumor
  • DNA Repair
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • RNA, Small Interfering
  • Y-Box-Binding Protein 1* / genetics
  • Y-Box-Binding Protein 1* / metabolism

Substances

  • RNA, Small Interfering
  • Y-Box-Binding Protein 1